Boehringer Mannheim responds to Genentech patent infringement suit.GAITHERSBURG, Md.--(HealthWire)--May 28, 1996--While we have not yet seen the court papers, we are aware of the lawsuit lawsuit: see procedure; tort. filed by Genentech and are confident that reteplase is covered by valid and enforceable patents in that it has a completely different molecular structure than other thrombolytic agents thrombolytic agent Clot-dissolving drug, thrombolytic An agent–eg, tPA, streptokinase, that effects thrombolysis and restores vascular patency–eg, in managing acute MIs. See Thrombolytic therapy, tPA. . We believe that as the facts of the case become known, this position will become apparent. "We do not believe the timing of this filing is coincidental co·in·ci·den·tal adj. 1. Occurring as or resulting from coincidence. 2. Happening or existing at the same time. co·in . On May 3, 1996, the Food and Drug Administration's Cardio-Renal Advisory Committee voted unanimously to recommend approval of reteplase," said John Melville, vice president of Boehringer Mannheim Corp., U.S. Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. Division. "This recent action by Genentech is not without precedent as they have a history of aggressively resisting new market entries that pose a threat to their market share. This filing is also indicative of their concerns about the strengths and advantages of reteplase." CONTACT: Boehringer Mannheim, Gaithersburg Kevin Kramer Kevin A. Kramer (born August 24th, 1976) is a television writer and producer. He has worked on the reality shows, The Biggest Loser, Beauty and The Geek, and Unan1mous. Kevin is currently writing for the Cartoon Network show, Chowder , 301/216-3733 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion